Ascletis Pharma Inc. (HKG:1672)
Hong Kong
· Delayed Price · Currency is HKD 16.51
-0.17 (-1.02%)
Apr 29, 2026, 4:08 PM HKT
Ascletis Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2.03 | 1.28 | 56.6 | 54.09 | 76.88 | Upgrade
|
| Revenue Growth (YoY) | 58.07% | -97.73% | 4.63% | -29.64% | 119.64% | Upgrade
|
| Cost of Revenue | 1.5 | 0.55 | 30.61 | 78.78 | 37.7 | Upgrade
|
| Gross Profit | 0.53 | 0.74 | 25.99 | -24.69 | 39.17 | Upgrade
|
| Selling, General & Admin | 75.23 | 101.74 | 116.02 | 52.18 | 50.82 | Upgrade
|
| Research & Development | 409.05 | 302.39 | 216.78 | 267.1 | 213.32 | Upgrade
|
| Other Operating Expenses | 0.77 | 1.23 | 2.14 | 4.64 | 5.5 | Upgrade
|
| Operating Expenses | 485.06 | 405.37 | 334.94 | 323.93 | 269.64 | Upgrade
|
| Operating Income | -484.53 | -404.63 | -308.95 | -348.62 | -230.47 | Upgrade
|
| Interest Expense | -0.16 | -0.24 | -0.14 | -0.16 | -0.13 | Upgrade
|
| Interest & Investment Income | 65.68 | 92.24 | 99.28 | 47.48 | 24.99 | Upgrade
|
| Earnings From Equity Investments | - | -5.27 | -20.28 | -22.89 | -17.88 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.67 | 4.15 | 9.7 | 60.18 | -16.44 | Upgrade
|
| Other Non Operating Income (Expenses) | 37.9 | 21.16 | 6.7 | 4.35 | 40.9 | Upgrade
|
| EBT Excluding Unusual Items | -386.79 | -292.61 | -213.69 | -259.65 | -199.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | 27.41 | 2.25 | 68.97 | - | - | Upgrade
|
| Asset Writedown | - | -10.58 | - | -55.19 | - | Upgrade
|
| Pretax Income | -359.37 | -300.94 | -144.72 | -314.84 | -199.02 | Upgrade
|
| Income Tax Expense | 0.51 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 | Upgrade
|
| Net Income | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 | Upgrade
|
| Net Income to Common | -359.88 | -300.94 | -144.72 | -314.84 | -199.02 | Upgrade
|
| Shares Outstanding (Basic) | 973 | 1,002 | 1,074 | 1,087 | 1,098 | Upgrade
|
| Shares Outstanding (Diluted) | 973 | 1,002 | 1,074 | 1,087 | 1,098 | Upgrade
|
| Shares Change (YoY) | -2.90% | -6.75% | -1.19% | -0.96% | 5.53% | Upgrade
|
| EPS (Basic) | -0.37 | -0.30 | -0.13 | -0.29 | -0.18 | Upgrade
|
| EPS (Diluted) | -0.37 | -0.30 | -0.13 | -0.29 | -0.18 | Upgrade
|
| Free Cash Flow | -416.78 | -343.67 | -230.01 | -209.53 | -151.9 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -0.34 | -0.21 | -0.19 | -0.14 | Upgrade
|
| Gross Margin | 25.99% | 57.29% | 45.92% | -45.65% | 50.96% | Upgrade
|
| Operating Margin | -23892.11% | -31538.04% | -545.88% | -644.51% | -299.79% | Upgrade
|
| Profit Margin | -17745.56% | -23455.65% | -255.70% | -582.07% | -258.88% | Upgrade
|
| Free Cash Flow Margin | -20551.08% | -26786.75% | -406.40% | -387.38% | -197.59% | Upgrade
|
| EBITDA | -471.65 | -390.45 | -294.89 | -322.49 | -204.83 | Upgrade
|
| EBITDA Margin | - | - | - | - | -266.45% | Upgrade
|
| D&A For EBITDA | 12.89 | 14.18 | 14.05 | 26.13 | 25.64 | Upgrade
|
| EBIT | -484.53 | -404.63 | -308.95 | -348.62 | -230.47 | Upgrade
|
| EBIT Margin | - | - | - | - | -299.79% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.